• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

G1 Therapeutics and Pepper Bio Ink Global License Agreement for Lerociclib

by Syed Hamza Sohail 05/01/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–       G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for all indications outside acute radiation syndrome (ARS).

–       As Pepper Bio’s first in-licensed therapeutic, lerociclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). The therapeutic has previously demonstrated impressive efficacy in clinical studies across various cancer types, including two completed Phase 3 clinical trials in HR+/Her2- metastatic breast cancer. 

Pepper Bio Advances Liver Cancer Treatment with Lerociclib: A Breakthrough in Precision Medicine

Pepper Bio’s revolutionary transomics platform, COMPASS, is reshaping the landscape of drug discovery by offering a comprehensive view of disease biology. By translating biological maps encompassing genomics, transcriptomics, proteomics, and phosphoproteomics, COMPASS provides researchers with unprecedented insights into the real-time function of proteins, revolutionizing drug development methodologies. Leveraging COMPASS, Pepper Bio identified CDK4 and CDK6 as promising targets in hepatocellular carcinoma (HCC), the most prevalent form of liver cancer and the third leading cause of cancer-related deaths.

In a significant milestone, Pepper Bio conducted preclinical testing of lerociclib, a potential therapeutic for HCC, demonstrating superior efficacy compared to standard care both during and after dosing. This success led to an in-licensing agreement, marking lerociclib as Pepper Bio’s inaugural therapeutic slated for Phase 2 clinical trials.

Under this partnership, Pepper Bio gains exclusive rights to develop, manufacture, and commercialize lerociclib for non-ARS indications across major global markets, excluding the Asia-Pacific region licensed to Genor Biopharma. Collaborating closely with G1 Therapeutics, Pepper Bio aims to seamlessly transition lerociclib through clinical trials and regulatory approval processes.

This development follows Pepper Bio’s oversubscribed seed funding round, supported by notable investors such as NFX, Silverton Partners, and Merck Digital Sciences Studio. With these resources, Pepper Bio is poised to initiate clinical development programs for lerociclib, with the overarching objective of expediting regulatory approvals and bringing this innovative therapy to patients worldwide.

The agreement outlines upfront payments to G1 totaling mid-single-digit millions, with potential milestone payments reaching up to $135M across three indications, alongside double-digit royalties on lerociclib’s annual net sales. This collaboration underscores the commitment of both parties to advancing precision medicine and addressing unmet medical needs in liver cancer treatment.

“Liver cancer is a real and devastating diagnosis for hundreds of thousands of patients each year. Adding lerociclib into our pipeline is a significant step forward in our mission to find treatments for untreatable diseases,” said Jon Hu, Chief Executive Officer and co-founder of Pepper Bio. “Lerociclib holds tremendous promise as a cornerstone of our oncology portfolio, and we are excited to leverage its potential to bring life-saving treatments to those in need.” 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |